BTK inhibitor + venetoclax, fixed duration
Block the survival signal and remove the death shield at the same time, for about a year, then stop and stay in remission for years.
CAPTIVATE and GLOW (ibrutinib), AMPLIFY (acalabrutinib; FDA approved February 2026), SEQUOIA arm D (zanubrutinib), and CELESTIAL (sonrotoclax + zanubrutinib) all show high uMRD and durable PFS after 12-15 months of therapy. Fixed duration reduces cumulative toxicity and cost versus indefinite BTK inhibition.
Pages like this
not linked directly; found by shared links- IdeaMRD-guided treatment duration in CLL
Shares CAPTIVATE, CELESTIAL-TNCLL, Sonrotoclax, Zanubrutinib.
- IdeaBTK degraders to pre-empt resistance in frontline CLL
Shares Sonrotoclax, Acalabrutinib, BTK (Bruton tyrosine kinase), BCL-2.
- Key paperELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL
Shares SEQUOIA, Acalabrutinib, Zanubrutinib, Ibrutinib.
- PairingCaution: chemoimmunotherapy in del(17p)/TP53 CLL
Shares SEQUOIA, Zanubrutinib, Venetoclax, Chronic lymphocytic leukaemia.
- TrialBELLWAVE-011
Shares Acalabrutinib, Ibrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.
- TrialCLL13 / GAIA
Shares AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients, Ibrutinib, BTK (Bruton tyrosine kinase), BCL-2.
- PairingCaution: ibrutinib in patients with cardiac risk
Shares Acalabrutinib, Zanubrutinib, Ibrutinib, Chronic lymphocytic leukaemia.
- TrialALPINE
Shares Zanubrutinib, Ibrutinib, BTK (Bruton tyrosine kinase), Chronic lymphocytic leukaemia.